

Asset highlights

- **Brief Description:** Pharmaceutical enterprise specializing in the development and production of insulin and other biotechnological medicines. The company is one of the few in Eastern Europe with a full-cycle insulin manufacturing process — from active pharmaceutical ingredient (API) synthesis to finished dosage forms.
- **Products / services:** Products for treatment of diabetes, antithrombotic products, antidotes, and metabolite products.
- **Technical Parameters:** Full technology cycle of insulin production.
- **Project Strengths:** Full production cycle, in-house designed technologies, 20 years on the market.
- **Target Market:** Pharmaceuticals.

Privatisation information

- **Share for sale:** 70.7%
- **Starting price:** ~\$15 mil
- **When:** IV quarter of 2026 – I quarter of 2027

Main financials, \$ mln

